Skip to main content
Vaxcell-Bio Therapeutics logo

Vaxcell-Bio Therapeutics — Investor Relations & Filings

Ticker · 323990 ISIN · KR7323990002 KO Manufacturing
Open in API
Filings indexed 228 across all filing types
Latest filing 2026-01-06 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 323990

About Vaxcell-Bio Therapeutics

https://vaxcell-bio.com/en/

Vaxcell-Bio Therapeutics is a biotechnology company specializing in the research and development of innovative immunotherapies. The company's primary focus is on oncology, developing a pipeline of cell-based and protein-based treatments, including immune cell therapies and targeted protein-degrading therapeutics. In addition to its core focus on cancer, Vaxcell-Bio is expanding its research into other areas, such as developing drug delivery system (DDS)-based therapies for conditions like macular degeneration.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically marked as a '정정신고' (Amendment Report). It details changes to previously reported stock option grants, including adjustments to the number of shares and the list of recipients. This type of disclosure regarding stock options and capital-related changes falls under the category of 'Share Issue/Capital Change' (SHA) as it pertains to the company's equity structure and incentive plans.
2026-01-06 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory filing from Vaxcell-Bio regarding a correction to a previously submitted 'Stock Option Grant' report. It details changes to the number of recipients and the total number of shares granted due to an employee's resignation. Since this is a specific regulatory disclosure regarding capital structure and share-based compensation (stock options) that does not fit into the other categories like 'Share Issue' or 'Director's Dealing', it is classified as a general regulatory filing.
2026-01-06 Korean
[기재정정]유형자산취득결정(자율공시)
Regulatory Filings
2025-11-05 Korean
본점소재지변경
Regulatory Filings
2025-11-05 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 1% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (Non-Deal Roadshow). It provides details such as the date, location, target audience, and purpose of the meeting. It is not the presentation itself, but an announcement of the event and the availability of materials, fitting the criteria for a Regulatory Filing (RNS) as it is a standard corporate disclosure of an event schedule.
2025-09-18 Korean
투자판단관련주요경영사항 (박스루킨-15주 (Vaxleukin-15 inj) 품목허가 변경신청 승인)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Major Management Matter' disclosure (투자판단 관련 주요경영사항). It details the approval of a product license change (Vaxleukin-15 inj) by the Animal and Plant Quarantine Agency. Since this is a specific regulatory disclosure regarding business operations and product approvals that does not fit into categories like financial reports, M&A, or director dealings, it is classified as a general regulatory filing.
2025-09-17 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.